GSK's hostile $2.6 bn bid for Human Genome Sciences

Wed, 05/09/2012 - 05:05 EDT - France24.com - Business

RDF10

British drugmaker GlaxoSmithKline on Wednesday said it had gone hostile over its $2.6 billion (2.0 billion-euro) takeover bid for US research partner Human Genome Sciences Inc.GlaxoSmithKline, which in April had an informal offer rejected by the US company's board, said it had decided to put its bid directly to the shareholders of HGS. The offer remains $13 per share in cash."GlaxoSmithKline plc today announced that it will ... commence a tender offer this week to acquire all of the outstanding shares of HGS for $13.0 per share in cash," the British firm said.

Original article
Login or register to post comments

GSK's hostile $2.6 bn bid for Human Genome Sciences
British drugmaker GlaxoSmithKline on Wednesday said it had gone hostile over its $2.6 billion (2.0 billion-euro) takeover bid for US research partner Human Genome Sciences Inc.GlaxoSmithKline, which in April had an informal offer rejected by the US company's board, said it had decided to put its bid directly to the shareholders of HGS. The offer remains $13 per share in cash."GlaxoSmithKline plc today announced that it will ... commence a tender offer this week to acquire all of the outstanding shares of HGS for $13.0 per share in cash," the British firm said.
GSK to go hostile with $2.6 billion Human Genome tender
LONDON (Reuters) - GlaxoSmithKline will take its $2.6 bil
Human Genome Sciences: Avoid This Sinking Ship
By Vatalyst: It has recently been reported that GlaxoSmithKline (GSK) has lined up alternative candidates to replace the entire board of directors of Human Genome Sciences (HGSI).
Human Genome Sciences - Investors Are Speculating On A Higher Bid
By Robert Broens: Shares of Human Genome Sciences (HGSI) almost doubled today after GlaxoSmithKline made a $13 offer for the company. Shares ended the day 98% higher to close at $14.17
Will Realism Prevail As GlaxoSmithKline Goes Hostile With $6.2 Billion Human Genome Sciences Bid?
By Proactive Investor: Shares in GlaxoSmithKline (GSK) fell in Wednesday morning trade in London after it went hostile with its bid to acquire the American biotech Human Genome Sciences (HGSI).
Human Genome Sciences: Analyzing The Road Ahead Now That It Is In Play
By Helix Investment Management:Headlines in the biotechnology sector are frequently dominated by M&A news, and as of April 19, there is a new M&A headline to discuss and analyze.
GSK clinches deal to buy Human Genome for $3 billion
LONDON (Reuters) - Glaxo
4 Biotech Stocks Beyond Human Genome Sciences To Consider Now
By Vatalyst: Buyout and takeover news usually rocks the market, and the potential changes concerning Human Genome Sciences (HGSI) and GlaxoSmithKline (GSK) are no exception.
What Does GlaxoSmithKline See In Human Genome Sciences?
By Income Hunter:Recently, Human Genome Sciences (HGSI) chose to reject a $2.59 billion takeover bid by GlaxoSmithKline (GSK).

Main menu

Secondary menu

GSK's hostile $2.6 bn bid for Human Genome Sciences

Related

Latest

User login

Our Blog

Markets Map

Follow Us

Secondary menu